Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
Saved in:
| Title: | Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. |
|---|---|
| Authors: | He, Chaoneng1,2 (AUTHOR), Mi, Xiufang2 (AUTHOR), Xu, Gaoqi2 (AUTHOR), Xu, Xinglu2 (AUTHOR), Xin, Wenxiu2 (AUTHOR), Zhong, Like2 (AUTHOR), Zhu, Junfeng2 (AUTHOR), Shu, Qi2 (AUTHOR), Fang, Luo2 (AUTHOR) dinghy@zjcc.org.cn, Ding, Haiying2,3 (AUTHOR) dinghy@zjcc.org.cn |
| Source: | PLoS ONE. 5/15/2024, Vol. 19 Issue 5, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 19326203 |
|---|---|
| DOI: | 10.1371/journal.pone.0302961 |
